Recent Quotes
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

22.69 -0.22 (-0.96%)
Streaming Delayed Price Updated: 2:26 PM EST, Feb 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 570,695
Open 22.83
Bid (Size) 22.68 (500)
Ask (Size) 22.72 (300)
Prev. Close 22.91
Today's Range 22.48 - 23.14
52wk Range 18.41 - 43.54
Shares Outstanding 70,814,462
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE
From SkyMedia, LLC
Via GlobeNewswire
News headline image
RARE CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx (RARE) Investors of Securities Class Action Deadline on April 6, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire

Performance

YTD
-3.9%
-3.9%
1 Month
-6.7%
-6.7%
3 Month
-32.8%
-32.8%
6 Month
-24.6%
-24.6%
1 Year
-44.4%
-44.4%

More News

Read More
News headline image
Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit Seeks Recovery for Investors; April 6, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit Seeks Recovery for Investors; April 6, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARE
From Pomerantz LLP
Via GlobeNewswire
News headline image
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Ultragenyx to Participate at Investor Conferences in March
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Pharmaceutical Inc. (RARE) Investors: April 6, 2026, Deadline in Securities Fraud Class Action Lawsuit
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Ultragenyx Pharmaceutical Inc. (RARE) Investors: April 6, 2026, Deadline in Securities Fraud Class Action Lawsuit
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder ↗
Via Stocktwits
News headline image
Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action Lawsuit Filed; April 6, 2026, Lead Plaintiff Deadline
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action Lawsuit Filed; April 6, 2026, Lead Plaintiff Deadline
Via NewMediaWire
Topics Fraud Lawsuit
Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit: Investors Face April 6, 2026, Deadline
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit: Investors Face April 6, 2026, Deadline
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
NASDAQ: RARE: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc.
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
NASDAQ: RARE: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc.
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
RARE INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE
From SkyMedia, LLC
Via GlobeNewswire
News headline image
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Stockholders Who Lost Money Investing in Ultragenyx Pharmaceutical Inc. Should Contact Robbins LLP for Information About Recovering Their Losses from RARE
From Robbins LLP
Via GlobeNewswire
News headline image
CLASS ACTION ALERTS: Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ultragenyx and Mereo BioPharma and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire

Frequently Asked Questions

Is Ultragenyx Pharmaceutical Inc. - Common Stock publicly traded?
Yes, Ultragenyx Pharmaceutical Inc. - Common Stock is publicly traded.
What exchange does Ultragenyx Pharmaceutical Inc. - Common Stock trade on?
Ultragenyx Pharmaceutical Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock?
The ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock is RARE on the Nasdaq Stock Market
What is the current price of Ultragenyx Pharmaceutical Inc. - Common Stock?
The current price of Ultragenyx Pharmaceutical Inc. - Common Stock is 22.69
When was Ultragenyx Pharmaceutical Inc. - Common Stock last traded?
The last trade of Ultragenyx Pharmaceutical Inc. - Common Stock was at 02/26/26 02:26 PM ET
What is the market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock?
The market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock is 1.61B
How many shares of Ultragenyx Pharmaceutical Inc. - Common Stock are outstanding?
Ultragenyx Pharmaceutical Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>